Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
422.8 USD | +0.90% | +5.41% | +3.91% |
May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
May. 07 | FOMO is Back |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.91% | 109B | B+ | ||
+10.87% | 105B | B+ | ||
+1.28% | 22.25B | B | ||
-13.14% | 22.09B | B+ | ||
-7.05% | 18.68B | A- | ||
-38.36% | 17.58B | A- | ||
-10.66% | 16.85B | B | ||
+3.75% | 13.76B | C+ | ||
+36.70% | 12.46B | C+ | ||
+295.70% | 8.12B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VRTX Stock
- Ratings Vertex Pharmaceuticals Incorporated